SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Attention Sarepta Therapeutics, Inc. Investors: Sarepta Misled Investors According to a Recently Filed Class Action

SAN DIEGO and CAMBRIDGE, Mass., Feb. 4, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Massachusetts.  The complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between July 24, 2013 and November 12, 2013 (the "Class Period").  Sarepta is a biopharmaceutical company that develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Sarepta Is Accused of Misstating the Significance of Eteplirsen Data Set

According to the complaint, Sarepta shares initially fell $3.26 per share, or 7.8%, to close at $38.63 per share on October 30, 2013, following the publication of reports challenging the significance of Sarepta's Phase IIb eteplirsen study data set.  Then, Sarepta shares fell an additional $23.40 per share, or 64%, to close at $13.16 on November 12, 2013, following the company's announcement that the Food and Drug Administration informed Sarepta that it considered its New Drug Application ("NDA") filing for  eteplirsen to be premature. 

According to the complaint, Sarepta misled investors by making materially false and misleading statements regarding the significance of its eteplirsen Phase IIb study data set and the likelihood of the FDA accepting the company's NDA for eteplirsen for review based on that data set.  As a result, Sarepta's common stock traded at artificially high prices throughout the class period.

Sarepta Shareholders Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo

If you invested in Sarepta and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, [email protected], or via the information form on the firm's shareholder rights blog: www.robbinsarroyo.com/shareholders-rights-blog/sarepta-therapeutics-inc

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. 

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
[email protected]
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

SOURCE Robbins Arroyo LLP

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.